Age and Disease Severity as Determinants of Stem Cell Fitness in Autologous HSCT for Systemic Sclerosis: Implications for Exhaustion-Driven Outcomes

Selected angle: source

One-sentence thesis

The cited A/B receipts support a specific working claim: Thrombotic microangiopathy may affect multiple systems and occurs in ~30% of patients undergoing hematopoietic stem cell transplantation; AKI occurs commonly after stem cell transplant, affecting 10%-73% of patients. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.

Interpretation note: This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

Why this is surprising

The critical, underappreciated role of patient age and baseline disease severity in modulating stem cell therapy efficacy, suggesting that stem cell exhaustion may drive differential outcomes in autoimmune and metabolic disorders, despite overall positive trends.

Known / obvious (do not republish): Overall survival rates exceed 90% in pediatric HCT recipients; Stem cell therapy reduces HbA1c and C-peptide in diabetic patients; Non-relapse mortality in HSCT has decreased significantly over decades

Real tension: High response rates (88.7%) in systemic sclerosis HSCT versus significantly lower PFS in older patients with high skin scores

Evidence Landscape

Bounded research question: Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?

Evidence receipts

• fact_id=138939 (A_core) — Thrombotic microangiopathy may affect multiple systems and occurs in ~30% of patients undergoing hematopoietic stem cell transplantation. doi=10.2147/jbm.s102235
• fact_id=103924 (A_core) — AKI occurs commonly after stem cell transplant, affecting 10%-73% of patients. doi=10.2215/cjn.08580719
• fact_id=186464 (A_core) — Acute heart failure has an incidence ranging from 0.4% to 2.2%. doi=10.1161/cir.0000000000001220
• fact_id=175615 (A_core) — overall survival was 90% doi=10.3324/haematol.2019.230128
• fact_id=145105 (A_core) — overall survival rates now > 90% in children less than 14 years of age. doi=10.1007/s12325-017-0636-2

What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

Limitations

• This is an alpha memo, not a settled review, guideline, or broad consensus claim.
• This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
• Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
• Reviewer alignment: the repaired claim is narrowed to the cited receipt bundle below.
• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

What would weaken this

• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

Strongest counter-evidence

• Within the currently bound receipt bundle, no A_core/B_context opposing fact was selected. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence.